Akèy › Kansè poumon › Kentucky › Lexington
Etid klinik pou Kansè poumon nan Lexington, KY
18 etid pou Kansè poumon ap chèche patisipan nan sit nan ak bò kote Lexington (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Ap rekriteFaz 3
- University of Kentucky/Markey Cancer Center, Lexington
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- Baptist Health Lexington, Lexington
- Baptist Health Hamburg, Lexington
- University of Kentucky/Markey Cancer Center, Lexington
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
Ap rekriteFaz 2
- University of Kentucky Chandler Medical Center ( Site 0019), Lexington
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- CommonSpirit Saint Joseph Hospital - Lexington, Lexington
- Saint Joseph Radiation Oncology Resource Center, Lexington
- CommonSpirit Saint Joseph Medical Center - East Lexington, Lexington
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Ap rekriteFaz 2/3
- Baptist Health Lexington, Lexington
- University of Kentucky Chandler Medical Center, Lexington
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Ap rekriteFaz 2/3
- Baptist Health Lexington, Lexington
- University of Kentucky Chandler Medical Center (UKCMC) - Markey Cancer Center (Lucille P. Markey Cancer Center), Lexington
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
Ap rekriteFaz 1/2
- University of Kentucky/Markey Cancer Center, Lexington
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 3
- CHI Saint Joseph Cancer Center - East, Lexington
- University of Kentucky Chandler Medical Center, Lexington
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Ap rekriteFaz 2
- University of Kentucky ( Site 0019), Lexington
EXoPERT EMERALD Clinical Study
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Lexington VA Healthcare System, Lexington
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- University of Kentucky/Markey Cancer Center, Lexington
Pathways, a Hope Intervention to Support Personal Goal Pursuit, Mental Health, and Quality of Life During Advanced Lung Cancer Treatment
Ap rekrite
- University of Kentucky, Lexington
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2/3
- University of Kentucky/Markey Cancer Center, Lexington
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- University of Kentucky/Markey Cancer Center, Lexington
Precision Lung Cancer Survivorship Care Intervention
Ap rekrite
- Markey Cancer Center, Lexington
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Ap rekriteFaz 1
- University of Kentucky Markey Cancer Center, Lexington
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Baptist Lexington, Lexington
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier
Ap rekriteEtid obsèvasyon
- Lexington VA Health Care System, Lexington
Etid Kansè poumon nan lòt vil
- Houston, TX78 etid
- Boston, MA62 etid
- New York City, NY60 etid
- Los Angeles, CA45 etid
- Arlington, VA41 etid
- Washington, DC41 etid
- Chicago, IL41 etid
- Baltimore, MD40 etid
- Nashville, TN40 etid
- St. Louis, MO39 etid
- Columbus, OH37 etid
- Philadelphia, PA36 etid
Lòt etid nan Lexington
- Kansè Poumon ki pa ti selil23 etid
- Kansè ovè16 etid
- Kansè pwostat14 etid
- Kansè (tout kalite)14 etid
- Kansè nan tete14 etid
- Kansè Metastatik11 etid
- Kansè kolorektal11 etid
- Ensifizyans kadyak11 etid
- Melanom10 etid
- Leksemi mieloïd egi10 etid
- Obèsite10 etid
- Karsinòm selil skuamèz tèt ak kou9 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.